Novartis’ big PhIII for canakinumab scores a surprise win helping heart attack patients
Novartis buildings in Basel, Switzerland, as seen from Dreirosenbruecke bridge
With its new heart drug Entresto struggling to find traction and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
